Top

12-01-2017 | Advanced breast cancer | Article

Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up

Journal: Breast Cancer Research and Treatment

Authors: Satomi Matsuo, Junichiro Watanabe, Koichi Mitsuya, Nakamasa Hayashi, Yoko Nakasu, Mitsuhiro Hayashi

Abstract

Purpose

The data of 589 metastatic breast cancer (MBC) patients in a single institution were reviewed to determine the outcomes of patients with brain metastasis (BM) and assess the efficacy of BM screening.

Methods

The patients with BM among the 589 MBC patients who underwent treatment at Shizuoka Cancer Center (Shizuoka, Japan) from 09/2002 to 03/2014 were retrospectively analyzed.

Results

During the study period, BM developed in 187 (31.7%) patients. The tumor subtypes were as follows: luminal (hormone receptor [HR]+, HER2−), 44.9%; luminal-HER2 (HR+, HER2+), 14.9%; HER2 (HR−, HER2+), 21.3%; and triple-negative (TN), 16.0%. BM was detected in 48.6% of the patients by screening MRI. While 137 of 187 patients underwent local therapy, whole-brain irradiation was the most frequently applied therapy (63.5%). The median overall survival from the diagnosis of BM was as follows: luminal, 7.0 months (M); luminal-HER2, 13.3 M; HER2, 17.7 M; TN, 4.2 M. The HER2 status (hazard ratio [HR]: 0.58, 95% confidence interval [CI] 0.38–0.88) and nonprogressive extracranial lesion(s) (HR: 0.45, 95% CI 0.29–0.71) were identified as prognostic factors in a multivariate analysis. When limited to HER2-overexpressed MBC patients, the multivariate analysis revealed that non-progressive extracranial lesion(s) (HR: 0.20, 95% CI 0.088–0.47) and stereotactic irradiation (STI) as an initial treatment (HR: 0.18, 95% CI 0.061–0.56) were prognostic factors.

Conclusions

Our retrospective review showed that early detection of BM by screening MRI, followed by STI, improved the prognosis of HER2-overexpressed MBC patients with BM. A further prospective randomized study is needed to confirm our findings.

Arvold ND, Oh KS, Niemieko A et al (2012) Brain metastases after breast-conserving therapy and systemic therapy: incidence and characteristics by biologic subtype. Breast Cancer Res Treat 136:153–160CrossRefPubMed

Barnholtz-Sloan JS, Solan AE, Davis FG et al (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance system. J Clin Oncol 22:2865–2872CrossRefPubMed

Miller KD, Weathers T, Haney LG et al (2003) Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 14:1072–1077CrossRefPubMed

Leyland-Jones B (2009) Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 27:5278–5286CrossRefPubMed

Lin NU, Jennifer RB, Eric PW (2004) CNS metastases in breast cancer. J Clin Oncol 22:3608–3617CrossRefPubMed

Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663CrossRefPubMed

Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior on breast cancer subtypes. J Clin Oncol 28:3271–3277CrossRefPubMed

Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcome in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645CrossRefPubMedPubMedCentral

Ramakrishna N, Temin S, Chandarlapaty S et al (2014) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american society of clinical oncology clinical practice guideline. J Clin Oncol 32:2001–2008CrossRef

10.

Gori S, Rimondini S, Anjelis VD et al (2007) Central nervous system metastases in HER-2-positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 12:766–773CrossRefPubMed

11.

Bendell JC, Domchek SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast cancer. Cancer 97:2972–2977CrossRefPubMed

12.

Brufsky AM, Mayer M, Rugo HS et al (2011) Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17:4834–4843CrossRefPubMed

13.

Niwinska A, Tacikowska M, Murawska M (2010) The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 77:1134–1139CrossRefPubMed

14.

Wolff AC, Hammond ME, Hicks DG et al (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed

15.

Sperduto PW, Kased N, Roberge D et al (2012) Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82:2111–2117CrossRefPubMed

16.

Niikura N, Hayashi N, Masuda N et al (2014) Treatment outcomes and prognostic factor for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis. Breast Cancer Res Treat 147:103–112CrossRefPubMed

17.

Eichler AF, Kuter I, Ryan R et al (2008) Survival in patients with brain metastases from breast cancer. Cancer 112:2359–2367CrossRefPubMed

18.

Braccini AL, Azria D, Thezenas S et al (2013) Prognostic factors of brain metastases from breast cancer: impact on targeted therapies. The Breast 22:993–998CrossRefPubMed

19.

Melisko ME, Moore DH, Sneed PK et al (2008) Brain metastases in breast cancer: clinical and pathologic characteristics associated with improvements in survival. J Neruooncol 88:359–365CrossRef

20.

Yust-Katz S, Garciarena P, Liu D et al (2013) Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol 114:229–235CrossRefPubMed

21.

Gauthier H, Guilhaume MN, Bidard FC et al (2010) Survival on breast cancer patients with meningeal carcinomatosis. Ann Oncol 21:2183–2187CrossRefPubMed

22.

Torrejon D, Oliveira M, Cortes J et al (2013) Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. The Breast 22:19–23CrossRefPubMed

23.

Niwinska AM, Rudnicka H, Murawska M (2011) Breast cancer carcinomatous meningitis: difference in survival depending on biological subtype, performance status, and treatment methods. J Clin Oncol 29:1073

24.

Hayashi N, Niikura N, Masuda N et al (2015) Prognostic factor or HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast Cancer Res Treat 149:277–284CrossRefPubMed

25.

Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942–948CrossRefPubMed

26.

Rusnak DW, Affleck K, Cockerill SG et al (2001) The characterization of Novel, Dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61:7196–7203PubMed

27.

Cameron D, Casey M, Press M et al (2008) A phase3 randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533–543CrossRefPubMed

28.

Bachelot T, Romieu G, Campone M et al (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71CrossRefPubMed

29.

Swain SM, Baselga J, Miles D et al (2014) Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase3 study CLEOPATRA. Ann Oncol 25:1116–1121CrossRefPubMedPubMedCentral

30.

Krop IE, Lin NU, Blackwell K et al (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26:113–119CrossRefPubMed

31.

Bartsch R, Berghoff AS, Preusser M (2014) Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J Neurooncol 116:205–206CrossRefPubMed

32.

Tsao MN, Rades D, Wirth A et al (2012) Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2:210–225CrossRefPubMedPubMedCentral

33.

Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13:1648–1655CrossRefPubMed

34.

Chang EL, Wefel JS, Hess KR et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol 10:1037–1044CrossRefPubMed

35.

Kocher M, Soffietti R, Abacioglu U et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29:134–141CrossRefPubMed

36.

Soffietti R, Kocher M, Abacioglu UM et al (2013) A European organization for research and treatment of cancer phaseIII trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumor after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31:65–72CrossRefPubMed

37.

Aoyama H, Tago M, Kato N et al (2007) Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388–1395CrossRefPubMed

38.

Matsunaga S, Shuto T, Kawahara N et al (2010) Gamma knife surgery for metastatic brain tumors from primary breast cancer: treatment indication based on number of tumors and breast cancer phenotype. J Neurosurg 113:65–72PubMed

39.

Kondziolka D, Kano H, Harrison GL et al (2011) Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. J Neurosurg 114:792–800CrossRefPubMed

40.

Alexander E 3rd, Moriarty TM, Davis RB et al (1995) Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Nati Cancer Inst 87:34–40CrossRef

41.

Yamamoto M, Serizawa T, Shuto T et al (2014) Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 15:387–395CrossRefPubMed